Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report

BACKGROUND: Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of vedolizumab on treatment of the patient with refractory pouchitis. CASE SUMMARY: A 32-year-old male with pancolonic ulcerative...

Descripción completa

Detalles Bibliográficos
Autor principal: Cakir, Ozlem Ozer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718792/
https://www.ncbi.nlm.nih.gov/pubmed/31531325
http://dx.doi.org/10.12998/wjcc.v7.i16.2316
_version_ 1783447798397534208
author Cakir, Ozlem Ozer
author_facet Cakir, Ozlem Ozer
author_sort Cakir, Ozlem Ozer
collection PubMed
description BACKGROUND: Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of vedolizumab on treatment of the patient with refractory pouchitis. CASE SUMMARY: A 32-year-old male with pancolonic ulcerative colitis since the age of 25 with primary failure of infliximab and mesalamine and intolerance of azathioprine, underwent a total proctocolectomy with ileal pouch-anal anastomosis in 2012. He developed chronic diarrhea in 2014, which was watery, 30 per day and accompanied with blood and mucus affecting his quality of life. CONCLUSION: Vedolizumab is safe and effective in the management of anti-tumor necrosis factor alpha refractory pouchitis.
format Online
Article
Text
id pubmed-6718792
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-67187922019-09-17 Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report Cakir, Ozlem Ozer World J Clin Cases Case Report BACKGROUND: Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of vedolizumab on treatment of the patient with refractory pouchitis. CASE SUMMARY: A 32-year-old male with pancolonic ulcerative colitis since the age of 25 with primary failure of infliximab and mesalamine and intolerance of azathioprine, underwent a total proctocolectomy with ileal pouch-anal anastomosis in 2012. He developed chronic diarrhea in 2014, which was watery, 30 per day and accompanied with blood and mucus affecting his quality of life. CONCLUSION: Vedolizumab is safe and effective in the management of anti-tumor necrosis factor alpha refractory pouchitis. Baishideng Publishing Group Inc 2019-08-26 2019-08-26 /pmc/articles/PMC6718792/ /pubmed/31531325 http://dx.doi.org/10.12998/wjcc.v7.i16.2316 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Cakir, Ozlem Ozer
Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
title Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
title_full Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
title_fullStr Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
title_full_unstemmed Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
title_short Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
title_sort effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718792/
https://www.ncbi.nlm.nih.gov/pubmed/31531325
http://dx.doi.org/10.12998/wjcc.v7.i16.2316
work_keys_str_mv AT cakirozlemozer effectivenessofvedolizumabtreatmentintwodifferentantitumornecrosisfactoralpharefractorypouchitisacasereport

Ejemplares similares